• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提高 MVA 病毒产量的高密度细胞培养。

High-cell-density cultivations to increase MVA virus production.

机构信息

Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany.

Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstr. 1, 39106 Magdeburg, Germany.

出版信息

Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9.

DOI:10.1016/j.vaccine.2017.10.112
PMID:29433897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7115588/
Abstract

Increasing the yield and the productivity in cell culture-based vaccine manufacturing using high-cell-density (HCD) cultivations faces a number of challenges. For example, medium consumption should be low to obtain a very high concentration of viable host cells in an economical way but must be balanced against the requirement that accumulation of toxic metabolites and limitation of nutrients have to be avoided. HCD cultivations should also be optimized to avoid unwanted induction of apoptosis or autophagy during the early phase of virus infection. To realize the full potential of HCD cultivations, a rational analysis of the cultivation conditions of the appropriate host cell line together with the optimal infection conditions for the chosen viral vaccine strain needs to be performed for each particular manufacturing process. We here illustrate our strategy for production of the modified vaccinia Ankara (MVA) virus isolate MVA-CR19 in the avian suspension cell line AGE1.CR.pIX at HCD. As a first step we demonstrate that the adjustment of the perfusion rate strictly based on the measured cell concentration and the glucose consumption rate of cells enables optimal growth in a 0.8 L bioreactor equipped with an ATF2 system. Concentrations up to 57 × 10 cells/mL (before infection) were obtained with a viability exceeding 95%, and a maximum specific cell growth rate of 0.019 h (doubling time = 36.5 h). However, not only the cell-specific MVA-CR19 virus yield but also the volumetric productivity was reduced compared to infections at conventional-cell-density (CCD). To facilitate optimization of the virus propagation phase at HCD, a larger set of feeding strategies was analyzed in small-scale cultivations using shake flasks. Densities up to 63 × 10 cells/mL were obtained at the end of the cell growth phase applying a discontinuous perfusion mode (semi-perfusion) with the same cell-specific perfusion rate as in the bioreactor (0.060 nL/(cell d)). At this cell concentration, a medium exchange at time of infection was required to obtain expected virus yields during the first 24 h after infection. Applying an additional fed-batch feeding strategy during the whole virus replication phase resulted in a faster virus titer increase during the first 36 h after infection. In contrast, a semi-continuous virus harvest scheme improved virus accumulation and recovery at a rather later stage of infection. Overall, a combination of both fed-batch and medium exchange strategies resulted in similar cell-specific virus yields as those obtained for CCD processes but 10-fold higher MVA-CR19 titers, and four times higher volumetric productivity.

摘要

在基于细胞培养的疫苗生产中,提高产量和生产力,使用高密度(HCD)培养面临许多挑战。例如,为了以经济的方式获得非常高浓度的存活宿主细胞,培养基消耗应该很低,但必须平衡积累有毒代谢物和限制营养物质的要求。HCD 培养也应进行优化,以避免在病毒感染的早期阶段发生不必要的细胞凋亡或自噬。为了充分发挥 HCD 培养的潜力,需要针对每种特定的生产工艺,对适当的宿主细胞系的培养条件进行合理分析,并对所选病毒疫苗株的最佳感染条件进行优化。在这里,我们举例说明了我们在 HCD 下使用禽悬浮细胞系 AGE1.CR.pIX 生产改良痘苗安卡拉(MVA)病毒株 MVA-CR19 的策略。作为第一步,我们证明了根据测量的细胞浓度和细胞的葡萄糖消耗率严格调整灌注率,可以在配备 ATF2 系统的 0.8 L 生物反应器中实现最佳生长。在感染前,可获得高达 57×10 个细胞/mL(细胞浓度)的浓度,存活率超过 95%,最大比细胞生长速率为 0.019 h(倍增时间=36.5 h)。然而,与在常规细胞密度(CCD)下的感染相比,不仅细胞特异性的 MVA-CR19 病毒产量,而且体积生产率也降低了。为了便于在 HCD 下优化病毒繁殖阶段,我们在摇瓶中进行了小规模培养,分析了更大的一组进料策略。在细胞生长阶段结束时,采用与生物反应器中相同的细胞特异性灌注率(0.060 nL/(细胞·d))的不连续灌注模式(半灌注),可获得高达 63×10 个细胞/mL 的密度。在这个细胞浓度下,在感染时需要进行培养基交换,以在感染后 24 小时内获得预期的病毒产量。在整个病毒复制阶段应用额外的补料分批进料策略,可在感染后 36 小时内导致病毒滴度更快增加。相比之下,半连续病毒收获方案可改善感染后期的病毒积累和恢复。总体而言,补料分批和培养基交换策略的结合可产生与 CCD 工艺相同的细胞特异性病毒产量,但 MVA-CR19 滴度高 10 倍,体积生产率高 4 倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/19aaf4b5218e/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/603fb1699566/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/a3deff78035e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/a33016404f51/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/199b5c8035ee/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/29c2301c7173/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/19aaf4b5218e/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/603fb1699566/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/a3deff78035e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/a33016404f51/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/199b5c8035ee/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/29c2301c7173/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e94/7115588/19aaf4b5218e/gr6_lrg.jpg

相似文献

1
High-cell-density cultivations to increase MVA virus production.提高 MVA 病毒产量的高密度细胞培养。
Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9.
2
High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.使用 ATF 系统的杂交补料分批/灌注策略生产高滴度 MVA 和流感 A 病毒。
Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035. doi: 10.1007/s00253-019-09694-2. Epub 2019 Feb 23.
3
Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.用于高细胞密度和连续多阶段培养的生物反应器:基于细胞培养的病毒疫苗生产中的过程强化选项。
Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32. doi: 10.1007/s00253-015-7267-9. Epub 2016 Jan 13.
4
High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.使用悬浮细胞通过交替切向流(ATF)灌注进行高细胞密度培养以生产甲型流感病毒。
Vaccine. 2014 May 19;32(24):2770-81. doi: 10.1016/j.vaccine.2014.02.016. Epub 2014 Feb 25.
5
Production of Modified Vaccinia Ankara Virus by Intensified Cell Cultures: A Comparison of Platform Technologies for Viral Vector Production.强化细胞培养生产改良安卡拉痘苗病毒:病毒载体生产平台技术比较。
Biotechnol J. 2021 Jan;16(1):e2000024. doi: 10.1002/biot.202000024. Epub 2020 Sep 8.
6
Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems.在两阶段半连续和连续搅拌罐培养系统中高效稳定地生产改良安卡拉痘病毒。
PLoS One. 2017 Aug 24;12(8):e0182553. doi: 10.1371/journal.pone.0182553. eCollection 2017.
7
Process intensification strategies toward cell culture-based high-yield production of a fusogenic oncolytic virus.基于细胞培养的溶瘤病毒高产的强化策略。
Biotechnol Bioeng. 2023 Sep;120(9):2639-2657. doi: 10.1002/bit.28353. Epub 2023 Feb 21.
8
Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.在一次性使用的轨道式摇床生物反应器中,使用 ATF 或 TFF 灌注系统生产甲型流感病毒。
Vaccine. 2019 Nov 8;37(47):7011-7018. doi: 10.1016/j.vaccine.2019.06.005. Epub 2019 Jun 29.
9
Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.利用新型猪悬浮细胞系 PBG.PK2.1 实现高细胞密度下的高效流感 A 病毒生产。
Vaccine. 2019 Nov 8;37(47):7019-7028. doi: 10.1016/j.vaccine.2019.04.030. Epub 2019 Apr 17.
10
Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production.细胞高密度培养和病毒疫苗生产的灌注控制。
Methods Mol Biol. 2020;2095:141-168. doi: 10.1007/978-1-0716-0191-4_9.

引用本文的文献

1
High Cell Density Perfusion Process of Quail Cells Producing Oncolytic rVSV-NDV.生产溶瘤性rVSV-NDV的鹌鹑细胞的高细胞密度灌注工艺
Eng Life Sci. 2025 Jul 14;25(7):e70035. doi: 10.1002/elsc.70035. eCollection 2025 Jul.
2
Perfusion process with tangential flow filtration for oncolytic VSV-GP production.采用切向流过滤进行溶瘤性水疱性口炎病毒糖蛋白(VSV-GP)生产的灌注过程。
Front Bioeng Biotechnol. 2025 May 30;13:1588293. doi: 10.3389/fbioe.2025.1588293. eCollection 2025.
3
Intensification of rAAV Production Based on HEK293 Cell Transient Transfection.

本文引用的文献

1
Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.用于高细胞密度和连续多阶段培养的生物反应器:基于细胞培养的病毒疫苗生产中的过程强化选项。
Appl Microbiol Biotechnol. 2016 Mar;100(5):2121-32. doi: 10.1007/s00253-015-7267-9. Epub 2016 Jan 13.
2
Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.大流行前和大流行期间流感疫苗的MVA平台的市场实施:一项关键意见领袖定量分析。
Vaccine. 2015 Aug 20;33(35):4349-58. doi: 10.1016/j.vaccine.2015.04.086. Epub 2015 Jun 3.
3
基于HEK293细胞瞬时转染的重组腺相关病毒(rAAV)生产强化
Biotechnol J. 2025 Jun;20(6):e70020. doi: 10.1002/biot.70020.
4
Advancing ORFV-Based Therapeutics to the Clinical Stage.将基于羊口疮病毒的疗法推进到临床阶段。
Rev Med Virol. 2025 May;35(3):e70038. doi: 10.1002/rmv.70038.
5
Digital Twin for Continuous Production of Virus-like Particles toward Autonomous Operation.用于连续生产病毒样颗粒以实现自主运行的数字孪生。
ACS Omega. 2024 Jul 25;9(32):34990-35013. doi: 10.1021/acsomega.4c04985. eCollection 2024 Aug 13.
6
Enhancing Virus with Celcradle™ Bioreactor: A Comparative Study with Traditional Cell Culture Methods.使用Celcradle™生物反应器增强病毒:与传统细胞培养方法的比较研究。
Vaccines (Basel). 2024 May 22;12(6):563. doi: 10.3390/vaccines12060563.
7
Animal Cell Lines as Expression Platforms in Viral Vaccine Production: A Post Covid-19 Perspective.动物细胞系作为病毒疫苗生产中的表达平台:后新冠疫情视角
ACS Omega. 2024 Apr 2;9(15):16904-16926. doi: 10.1021/acsomega.3c10484. eCollection 2024 Apr 16.
8
Extracellular vesicle depletion and UGCG overexpression mitigate the cell density effect in HEK293 cell culture transfection.细胞外囊泡清除和UGCG过表达减轻了HEK293细胞培养转染中的细胞密度效应。
Mol Ther Methods Clin Dev. 2024 Jan 17;32(1):101190. doi: 10.1016/j.omtm.2024.101190. eCollection 2024 Mar 14.
9
Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.生产无感染性病毒的抗病毒“OP7 嵌合体”缺陷干扰颗粒。
Appl Microbiol Biotechnol. 2024 Dec;108(1):97. doi: 10.1007/s00253-023-12959-6. Epub 2024 Jan 13.
10
Efficient production of protein complexes in mammalian cells using a poxvirus vector.利用痘病毒载体在哺乳动物细胞中高效生产蛋白复合物。
PLoS One. 2022 Dec 15;17(12):e0279038. doi: 10.1371/journal.pone.0279038. eCollection 2022.
The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis.
通过代谢通量分析表征的禽细胞系AGE1.CR.pIX。
BMC Biotechnol. 2014 Jul 30;14:72. doi: 10.1186/1472-6750-14-72.
4
Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases.安卡拉痘苗病毒(MVA)作为抗流感和其他病毒性呼吸道疾病疫苗的生产平台。
Viruses. 2014 Jul 17;6(7):2735-61. doi: 10.3390/v6072735.
5
High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.使用悬浮细胞通过交替切向流(ATF)灌注进行高细胞密度培养以生产甲型流感病毒。
Vaccine. 2014 May 19;32(24):2770-81. doi: 10.1016/j.vaccine.2014.02.016. Epub 2014 Feb 25.
6
Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor.在一次性使用的中空纤维生物反应器中培养贴壁和悬浮 MDCK 细胞生产高滴度人甲型流感病毒。
Vaccine. 2014 Feb 12;32(8):1003-11. doi: 10.1016/j.vaccine.2013.11.044. Epub 2013 Nov 19.
7
Clinical applications of attenuated MVA poxvirus strain.减毒 MVA 痘苗病毒株的临床应用。
Expert Rev Vaccines. 2013 Dec;12(12):1395-416. doi: 10.1586/14760584.2013.845531. Epub 2013 Oct 30.
8
Oxygen supply in disposable shake-flasks: prediction of oxygen transfer rate, oxygen saturation and maximum cell concentration during aerobic growth.一次性摇瓶中的供氧:有氧生长过程中氧传递速率、氧饱和度和最大细胞浓度的预测。
Biotechnol Lett. 2013 Aug;35(8):1223-30. doi: 10.1007/s10529-013-1203-9. Epub 2013 Apr 17.
9
Clinical development of Modified Vaccinia virus Ankara vaccines.安卡拉痘苗病毒改良疫苗的临床研发。
Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21.
10
Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.在临床前研究中,改良安卡拉牛痘病毒的保护效力。
Vaccine. 2013 Sep 6;31(39):4235-40. doi: 10.1016/j.vaccine.2013.03.016. Epub 2013 Mar 21.